Comparative Pharmacology
Head-to-head clinical analysis: ACTOPLUS MET XR versus JANUMET XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTOPLUS MET XR versus JANUMET XR.
ACTOPLUS MET XR vs JANUMET XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ACTOPLUS MET XR combines pioglitazone, a thiazolidinedione that improves insulin sensitivity by activating PPAR-γ, and metformin, a biguanide that decreases hepatic glucose production and improves peripheral glucose uptake.
JANUMET XR is a combination of sitagliptin, a DPP-4 inhibitor, and metformin, a biguanide. Sitagliptin increases active incretin levels (GLP-1, GIP), enhancing glucose-dependent insulin secretion and reducing glucagon secretion. Metformin decreases hepatic glucose production, reduces intestinal glucose absorption, and improves insulin sensitivity.
Initial dose: 15 mg pioglitazone/500 mg metformin hydrochloride extended-release orally once daily with evening meal. Titrate based on glycemic response, maximum dose 45 mg pioglitazone/2000 mg metformin hydrochloride extended-release per day.
One tablet orally once daily, with evening meal; initial dose based on patient's current sitagliptin and metformin doses, or new patients: starting dose 50 mg sitagliptin/500 mg metformin XR; maximum dose 100 mg sitagliptin/2000 mg metformin XR per day.
None Documented
None Documented
Pioglitazone: terminal half-life 3-7 hours (parent), 16-24 hours (active metabolites); clinical effect sustained due to metabolites. Metformin: terminal half-life 6.2 hours (plasma), elimination prolonged in renal impairment (creatinine clearance <60 mL/min).
Sitagliptin: terminal half-life ~12.4 hours, allowing once-daily dosing. Metformin: terminal half-life ~6.2 hours in plasma, increased to ~17.6 hours in renal impairment.
Pioglitazone: predominantly hepatic metabolism, 15-30% excreted in urine as metabolites, ~20% in feces. Metformin: 90% renal excretion unchanged via glomerular filtration and tubular secretion.
Sitagliptin: ~79% excreted unchanged in urine via renal tubular secretion (active secretion) and glomerular filtration; ~13% undergoes hepatic metabolism; ~1% excreted in feces. Metformin: ~90% excreted unchanged in urine via active tubular secretion.
Category C
Category C
Thiazolidinedione/Biguanide Combination
DPP-4 Inhibitor/Biguanide Combination